DiaMedica Therapeutics Inc（DMAC）財務資料DMACDiaMedica Therapeutics Inc

Evaluating the bottom line, DiaMedica Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -114.62%, provide a clear picture of how effectively DMAC converts its operational activities into shareholder value.

In the context of the broader market, DMAC competes directly with industry leaders such as NGNE and MNPR. With a market capitalization of $467.54M, it holds a significant position in the sector. When comparing efficiency, DMAC's gross margin of N/A stands against NGNE's N/A and MNPR's N/A. Such benchmarking helps identify whether DiaMedica Therapeutics Inc is trading at a premium or discount relative to its financial performance.

DMAC has reported a consistent negative net income, with Q2 2026 showing a loss of -10.1 million USD, but it has a strong current ratio of 9.11, indicating good short-term financial health. The company is heavily investing in R&D, which may lead to future growth despite current losses.